Opendata, web and dolomites

SUMMIT SIGNED

Stepping Up mRNA Mutanome Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SUMMIT project word cloud

Explore the words cloud of the SUMMIT project. It provides you a very rough idea of what is the project "SUMMIT" about.

hallmark    vaccines    repertoire    efficient    disruptive    cells    cell    outgrowth    unaccounted    aberrations    directed    mechanisms    standards    pioneered    variants    memory    potent    genetic    countermeasures    cancers    clinical    trial    antigen    eliciting    nk    realization    extensive    vaccination    interdisciplinary    heterogeneity    building    mrna    mutanome    constraints    vaccine    seamless    vision    discovery    cancer    moved    mobilizing    counteracting    unaffected    showed    immune    scientific    scarcity    technological    heterogeneous    defects    tackled    presentation    mediated    effector    first    individual    wave    escape    compatible    full    ignite    care    resistance    solving    combination    immunotherapy    deciphering    drive    personalized    point    antibodies    translation    single    prediction    drug    human    strategies    health    spectrum    clonal    acute    immunosuppression    rational    spotlight    exhaustion    drugs    patient    treatment    neoepitope    mutations    immunity    mere    lived    algorithms    vaccinated    medical    universal    industrial    inform    efficacy    fundamentally    close    patients    clones    tumors    preclinical    tumor    mechanism    protocols    treatments   

Project "SUMMIT" data sheet

The following table provides information about the project.

Coordinator
TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH 

Organization address
address: FREILIGRATHSTRASSE 12
city: MAINZ
postcode: 55131
website: http://www.tron-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙482˙500 €
 EC max contribution 2˙482˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) coordinator 2˙482˙500.00

Map

 Project objective

Immunotherapy is expected to fundamentally change the treatment of cancer patients. Personalized vaccines eliciting immune responses against individual cancer mutations have moved into the spotlight. We have pioneered the field and moved ´cancer mutanome vaccines´ from a mere vision into a disruptive medical concept compatible with current standards of drug development and health care practice. Solving key scientific and technological challenges and building on extensive preclinical studies, we showed in a first-in-human trial potent tumor-directed immunity in every single vaccinated patient, and clinical activity of a novel mRNA-based mutanome vaccine. Given that mutations are a hallmark of cancer, mRNA mutanome vaccines are universal drugs the efficacy of which are unaffected by the cancer type. The aim of this proposal is to ignite the next wave of advancement by addressing four key constraints challenging a full clinical realization of such vaccines. We will address the scarcity of point mutations in many tumors by extending neoepitope discovery to the full spectrum of genetic aberrations. Cancers are heterogeneous and outgrowth of clones unaccounted for by the vaccine is an efficient escape mechanism. We will develop neoepitope prediction algorithms deciphering clonal heterogeneity to inform rational vaccine design and countermeasures against selection of target escape variants. Tumor cell resistance to vaccine-induced T cells due to antigen presentation defects will be addressed by developing strategies for mobilizing the full repertoire of immune effector mechanisms, including antibodies and NK cells. T-cell exhaustion will be tackled by vaccination protocols promoting long-lived memory responses and by combination treatments counteracting tumor-mediated immunosuppression. Finally, we will drive the seamless clinical translation of the scientific findings by close interdisciplinary collaboration with strong and established clinical and industrial partners.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMMIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMMIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

TransTempoFold (2019)

A need for speed: mechanisms to coordinate protein synthesis and folding in metazoans

Read More  

TechChild (2019)

Just because we can, should we? An anthropological perspective on the initiation of technology dependence to sustain a child’s life

Read More  

DEEPTIME (2020)

Probing the history of matter in deep time

Read More